IFNGR2 genetic polymorphism associated with sex-specific paranoid schizophrenia risk

Nordic Journal of Psychiatry

Volumn 71, Issue 1, 2017, Pages 42-47

  Jemli, Achraf ^a   Inoubli, Oumaima ^a   Trifa, Fatma ^a,b   Mechri, Anouar ^c   Zaafrane, Ferid ^c   Gaha, Lotfi ^c   Jrad, Besma Bel Hadj ^a  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b CENTRE DE BIOTECHNOLOGIE DE SFAX   (Tunisia)

^c FATTOUMA BOURGUIBA UNIVERSITY HOSPITAL   (Tunisia)

Author keywords

behavioural disorders; genetic polymorphism; IFNGR2; male sex; paranoid schizophrenia; pro inflammatory cytokine

Indexed keywords

GAMMA INTERFERON RECEPTOR; GAMMA INTERFERON RECEPTOR 2; UNCLASSIFIED DRUG; IFNGR2 PROTEIN, HUMAN; INTERFERON RECEPTOR;

ADULT; AGE; ALLELE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC RISK; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PARANOID SCHIZOPHRENIA; PSYCHOLOGICAL RATING SCALE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SEX; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TUNISIAN; CLASSIFICATION; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; SCHIZOPHRENIA; TUNISIA;

ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, INTERFERON; SCHIZOPHRENIA; SCHIZOPHRENIA, PARANOID; TUNISIA;

EID: 84983800364     PISSN: 08039488     EISSN: 15024725     Source Type: Journal    
DOI: 10.1080/08039488.2016.1216595     Document Type: Article

References (54)

1. Owen MJ, Sawa A, Mortensen PB., Schizophrenia. Lancet 2016;388:86--97.
2. Gejman PV, Sanders AR, Duan J., The role of genetics in the etiology of schizophrenia. Psychiatr Clin North Am 2010;33:35–66.
3. Kronfol Z, Remick DG., Cytokines and the brain:Implications for clinical psychiatry. Am J Psychiatry 2000;157:683–94.
4. Elenkov I., Neuroendocrine effects on immune system. In:De Groot LJ, Beck-Peccoz P, Chrousos G, Dungan K, Grossman A, Hershman JM, et al., editors. Endotext [Internet]. South Dartmouth (MA):MDText.com, Inc; 2000–2009.
5. Maes M, Bosmans E, Meltzer HY, Scharpé S, Suy E., Interleukin-1 beta:A putative mediator of HPA axis hyperactivity in major depression? Am J Psychiatry 1993;150:1189–93.
6. Ganguli R, Brar JS, Chengappa KR, Deleo M, Yang ZW., Mitogen stimulated interleukin 2 production in never-medicated first episode schizophrenics-the influence of age of onset and negative symptoms. Arch Gen Psychiatry 1995;52:668–72.
7. Watanabe Y, Someya T, Nawa H., Cytokine hypothesis of schizophrenia pathogenesis:evidence from human studies and animal models. Psychiatry Clin Neurosci 2010;64:217–30.
8. Ho-Kyoung Y, Yong-Ku K., The T allele of the interferon-gamma +874A/T polymorphism is associated with bipolar disorder. Nord J Psychiatry 2012;66:14–18.
9. Hanisch UK., Microglia as a source and target of cytokines. Glia 2002;40:140–55.
10. Neumann H, Schmidt H, Wilharm E, Behrens L, Wekerle H., Interferon gamma gene expression in sensory neurons:Evidence for autocrine gene regulation. J Exp Med 2008;186:2023–31.
11. Taylor MW, Feng GS., Relationship between interferon gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 1991;5:2516–22.
12. Huh GS, Boulanger LM, Du H, Riquelme PA, Brotz TM, Shatz CJ., Functional requirement for class I MHC in CNS development and plasticity. Science 2000;290:2155–9.
13. Lee J, Kim SJ, Son TG, Chan SL, Mattson MP., Interferon-gamma is upregulated in the hippocampus in response to intermittent fasting and protects hippocampal neurons against excitotoxicity. J Neurosci Res 2006;83:1552–7.
14. Ottum PA, Arellano G, Reyes LI, Iruretagoyena M, Naves R., Opposing roles of interferon-gamma on cells of the central nervous system in autoimmune neuroinflammation. Front Immunol 2015;30:539.
15. Mogensen KE, Lewerenz M, Reboul J, Lutfalla G, Uze G., The type I interferon receptor:Structure, function, and evolution of a family business. J Interferon Cytokine Res 1999;19:1069–98.
16. Larkin JIII, Johnson HM, Subramaniam PS., Differential nuclear localization of the IFNGR-1 and IFNGR-2 subunits of the IFN-γ receptor complex following activation by IFN-γ. J Interferon Cytokine Res 2000;20:565–76.
17. DePaus RA, Kilic SS, Van Dissel JT, Van de Vosse E., Effect of amino acid substitutions in the human IFN-γR2 on IFN-γ responsiveness. Genes Immun 2011;12:136–44.
18. Nakashima H, Inoue H, Akahoshi M, Tanaka Y, Yamaoka K, Ogami E, et al. The combination of polymorphisms within interferon-gamma receptor 1 and receptor 2 associated with the risk of systemic lupus erythematosus. FEBS Lett 1999;453:187–90.
19. Schrijver HM, Hooper-van Veen T, Van Belzen MJ, Crusius JB, Pena AS, Barkhof F, et al. Polymorphisms in the genes encoding interferon-gamma and interferon-gamma receptors in multiple sclerosis. Eur J Immunogenet 2004;31:133–40.
20. Gao P-S, Mao X-Q, Jouanguy E, Pallier A, Doffinger R, Tanaka Y, et al. Nonpathogenic common variants of IFNGR1 and IFNGR2 in association with total serum IgE levels. Biochem Biophys Res Comm 1999;263:425–9.
21. Kay SR, Fiszbein A, Opler LA., The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–76.
22. Overall JE, Gorham DR., The brief psychiatric rating scale. Psychol Rep 1962;10:799–812.
23. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington (DC):American Psychiatric Association; 1994–2000.
24. Girgis RR, Kumar SS, Brown AS., The cytokine model of schizophrenia:Emerging therapeutic strategies. Biol Psychiatry 2014;75:292–9.
25. Turhan L, Batmaz S, Kocbiyik S, Soygur AH., The role of tumour necrosis factor alpha and soluble tumour necrosis factor alpha receptors in the symptomatology of schizophrenia. Nord J Psychiatry 2016;70:342–50.
26. Dasdemir S, Kucukali CI, Bireller ES, Tuzun E, Cakmakoglu B., Chemokine gene variants in schizophrenia. Nord J Psychiatry 2016;70:407–12.
27. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B., Meta-analysis of cytokine alterations in schizophrenia:Clinical status and antipsychotic effects. Biol Psychiatry 2011;70:663–71.
28. Drzyzga L, Obuchowicz E, Marcinowska A, Herman ZS., Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun 2006;20:532–45.
29. Kamińska T, Wysocka A, Marmurowska-Michalowska H, Dubas-Slemp H, Kandefer-Szerszeń M., Investigation of serum cytokine levels and cytokine production in whole blood cultures of paranoid schizophrenic patients. Arch Immunol Ther Exp (Warsz) 2001;496:439–45.
30. Kim YK, Myint AM, Lee BH, Han CS, Lee HJ, Kim DJ, et al. Th1, Th2 and Th3 cytokine alteration in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:1129–34.
31. Becker D, Kritschmann E, Floru S, Shlomo-David Y, Gotlieb-Stematsky T., Serum interferon in first psychotic attack. Br J Psychiatry 1990;157:136–8.
32. Gattaz WF, Dalgalarrondo P, Schröder HC., Abnormalities in serum concentrations of interleukin-2, interferon-alpha and interferon-gamma in schizophrenia not detected. Schizophr Res 1992;6:237–41.
33. Guo J, Liu C, Wang Y, Feng B, Zhang X., Role of T helper lymphokines in the immune-inflammatory pathophysiology of schizophrenia:Systematic review and meta-analysis. Nord J Psychiatry 2015;69:364–72.
34. Wysokiński A, Margulska A, Strzelecki D, Kłoszewska I., Levels of C-reactive protein (CRP) in patients with schizophrenia, unipolar depression and bipolar disorder. Nord J Psychiatry 2015;69:346–53.
35. Thabet S, Ben Nejma M, Zaafrane F, Gaha L, Ben Salem K, Romdhane A, et al. Association of the Met-196-Arg variation of human tumor necrosis factor receptor2 (TNFR2) with paranoid schizophrenia. J Mol Neurosci 2011;43:358–63.
36. Paul-Samojedny M, Kowalczyk M, Suchanek R, Owczarek A, Fila-Danilow A, Szczygiel A, et al. Functional polymorphism in the interleukin-6 and interleukin-10 genes in patients with paranoid schizophrenia-a case-control study. J Mol Neurosci 2010;42:112–19.
37. Dimitrov DH, Lee S, Yantis J, Honaker C, Braida N, Walss-Bass C., Elevated serum levels of high-sensitivity C-reactive proteins are associated with severe delusional symptoms in a subgroup of patients with schizophrenia. J Clin Psychiatry 2016;77:131–2.
38. Pusic AD, Pusic KM, Clayton BL, Kraig RP., IFNγ-stimulated dendritic cell exosomes as a potential therapeutic for remyelination. J Neuroimmunol 2014;266:12–23.
39. Grüber L, Bunse T, Weidinger E, Reichard H, Müller N., Adjunctive recombinant human interferon gamma-1b for treatment-resistant schizophrenia in 2 patients. J Clin Psychiatry 2014;75:1266–7.
40. Müller N, Myint M, Schwarz MJ., Kynurenine pathway in schizophrenia:Pathophysiological and therapeutic aspects. Curr Pharm Des 2011;17:130–6.
41. Kim IJ, Beck HN, Lein PJ, Higgins D., Interferon γ induces retrograde dendritic retraction and inhibits synapse formation. J Neurosci 2002;22:4530–9.
42. Goddard CA, Butts DA, Shatz CJ., Regulation of CNS synapses by neuronal MHC class I. Proc Natl Acad Sci U S A 2007;104:6828–33.
43. Bae HR, Leung PS, Tsuneyama K, Valencia JC, Hodge DL, Kim S, et al. Chronic expression of interferon gamma leads to murine autoimmune cholangitis with a female predominance. Hepatology 2016. [Epub ahead of print]. doi:10.1002/hep.28641.
44. Loisel DA, Tan Z, Tisler CJ, Evans MD, Gangnon RE, Jackson DJ, et al. IFNG genotype and sex interact to influence the risk of childhood asthma. J Allergy Clin Immunol 2011;128:524–31.
45. Morrison BA, Ucisik-Akkaya E, Flores H, Alaez C, Gorodezky C, Dorak MT., Multiple sclerosis risk markers in HLA-DRA, HLA-C, and IFNG genes are associated with sex-specific childhood leukemia risk. Autoimmunity 2010;43:690–7.
46. Goetzl EJ, Huang MC, Kon J, Patel K, Schwartz JB, Fast K, et al. Gender specificity of altered human immune cytokine profiles in Aging. FASEB J 2010;24:3580–9.
47. Booth M, Mwatha JK, Joseph S, Jones FM, Kadzo H, Ireri E, et al. Periportal fibrosis in human Schistosoma mansoni infection is associated with low IL-10, low IFN-gamma, high TNF-alpha, or low RANTES, depending on age and gender. J Immunol 2004;172:1295–303.
48. Bao M, Yang Y, Jun HS, Yoon JW., Molecular mechanisms for gender differences in susceptibility to T cell-mediated autoimmune diabetes in nonobese diabetic mice. J Immunol 2002;168:5369–75.
49. McFarland HI, Bigley NJ., Sex-dependent, early cytokine production by NK-like spleen cells following infection with the D variant of encephalomyocarditis virus (EMCV-D). Viral Immunol Fall 1989;2:205–14.
50. Disshon KA, Dluzen DE., Estrogen reduces acute striatal dopamine responses in vivo to the neurotoxin MPP + in female, but not male rats. Brain Res 2000;868:95–104.
51. Da Silva JA., Sex hormones and glucocorticoids:interactions with the immune system. Ann N Y Acad Sci 1999;876:102–17.
52. Ben Nejma M, Zaabar I, Zaafrane F, Thabet S, Mechri A, Gaha L, et al. A gender-specific association of interleukin 1 receptor antagonist polymorphism with schizophrenia susceptibility. Acta Neuropsychiatr 2013;25:349–55.
53. Xiang L, Rehm KE, Sunesara I, Griswold M, Marshall GD., Gene polymorphisms of stress hormone and cytokine receptors associate with immunomodulatory profile and psychological measurement. J Psychosom Res 2015;78:438–44.
54. Müller N, Weidinger E, Leitner B, Schwarz MJ., The role of inflammation in schizophrenia. Front Neurosci 2015;9:372.